134 related articles for article (PubMed ID: 31151091)
1. Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency.
Höybye C; Faseh L; Himonakos C; Pielak T; Eugen-Olsen J
Endocr Connect; 2019 Jun; 8(6):772-779. PubMed ID: 31151091
[TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
Persson M; Engström G; Björkbacka H; Hedblad B
Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
[TBL] [Abstract][Full Text] [Related]
3. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
Sørensen MH; Gerke O; Eugen-Olsen J; Munkholm H; Lambrechtsen J; Sand NP; Mickley H; Rasmussen LM; Olsen MH; Diederichsen A
Atherosclerosis; 2014 Nov; 237(1):60-6. PubMed ID: 25222341
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.
Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E
J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
Lyngbæk S; Marott JL; Sehestedt T; Hansen TW; Olsen MH; Andersen O; Linneberg A; Haugaard SB; Eugen-Olsen J; Hansen PR; Jeppesen J
Int J Cardiol; 2013 Sep; 167(6):2904-11. PubMed ID: 22909410
[TBL] [Abstract][Full Text] [Related]
8. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency.
Deepak D; Daousi C; Javadpour M; Clark D; Perry Y; Pinkney J; Macfarlane IA
Growth Horm IGF Res; 2010 Jun; 20(3):220-5. PubMed ID: 20185347
[TBL] [Abstract][Full Text] [Related]
9. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Predictor of Incident Atrial Fibrillation.
Westin O; Rasmussen LJH; Andersen O; Buch E; Olsen JE; Friberg J
J Atr Fibrillation; 2018 Apr; 10(6):1801. PubMed ID: 29988279
[TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
Toldi G; Bíró E; Szalay B; Stenczer B; Molvarec A; Rigó J; Vásárhelyi B; Bekõ G
Clin Chem Lab Med; 2011 Nov; 49(11):1873-6. PubMed ID: 21722073
[TBL] [Abstract][Full Text] [Related]
11. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
13. Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms.
Bigseth TT; Engh JA; Egeland J; Andersen E; Andreassen OA; Bang-Kittilsen G; Falk RS; Holmen TL; Lindberg M; Mordal J; Nielsen J; Steen NE; Ueland T; Vang T; Fredriksen M
BMC Psychiatry; 2021 Oct; 21(1):527. PubMed ID: 34702245
[TBL] [Abstract][Full Text] [Related]
14. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.
Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y
Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344
[TBL] [Abstract][Full Text] [Related]
15. Association of Adverse Experiences and Exposure to Violence in Childhood and Adolescence With Inflammatory Burden in Young People.
Rasmussen LJH; Moffitt TE; Arseneault L; Danese A; Eugen-Olsen J; Fisher HL; Harrington H; Houts R; Matthews T; Sugden K; Williams B; Caspi A
JAMA Pediatr; 2020 Jan; 174(1):38-47. PubMed ID: 31682707
[TBL] [Abstract][Full Text] [Related]
16. Soluble receptor for urokinase plasminogen activator in community-acquired pneumonia in children.
Wrotek A; Pawlik K; Jackowska T
Adv Exp Med Biol; 2013; 788():329-34. PubMed ID: 23835994
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study.
Hayek SS; Ko YA; Awad M; Ahmed H; Gray B; Hosny KM; Aida H; Tracy MJ; Wei C; Sever S; Reiser J; Quyyumi AA
Kidney Int Rep; 2017 May; 2(3):425-432. PubMed ID: 29142970
[TBL] [Abstract][Full Text] [Related]
18. Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels.
Gustafsson A; Ajeti V; Ljunggren L
Biomark Insights; 2011; 6():119-25. PubMed ID: 22084570
[TBL] [Abstract][Full Text] [Related]
19. Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation.
Koh AS; Velmurugan B; Gao F; Tan RS; Wong JI; Teo LLY; Keng BMH; Chua SJM; Yuan JM; Koh WP; Cheung C
BMC Geriatr; 2017 Nov; 17(1):275. PubMed ID: 29179674
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients?
Almroth G; Lönn J; Uhlin F; Nayeri F; Brudin L; Andersson B; Hahn-Zoric M
Scand J Immunol; 2013 Sep; 78(3):285-90. PubMed ID: 23721058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
